Paweł Nastałek
Jagiellonian University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paweł Nastałek.
European Respiratory Journal | 2013
Bernd Lamprecht; Lowie E.G.W. Vanfleteren; Michael Studnicka; Michael J. Allison; Mary Ann McBurnie; William M. Vollmer; Wan Cheng Tan; Rune Nielsen; Paweł Nastałek; Louisa Gnatiuc; Bernhard Kaiser; Christer Janson; Emiel F.M. Wouters; Peter Burney; A. Sonia Buist
For the same degree of lung function impairment females tend to report more (severe) dyspnoea and cough, but less phlegm http://ow.ly/mp2CF
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine | 2014
Agata Nizankowska-Jedrzejczyk; Fernanda R. Almeida; Alan A. Lowe; Aleksander Kania; Paweł Nastałek; Filip Mejza; Jonathan H. Foley; Ewa Nizankowska-Mogilnicka; Anetta Undas
STUDY OBJECTIVE Obstructive sleep apnea (OSA) is associated with systemic inflammation and a hypercoagulable state. The current study aim was to investigate whether mandibular advancement splint (MAS) therapy affects inflammatory and hemostatic parameters in patients with mild-to-moderate OSA. METHODS Twenty-two patients with mild-to-moderate OSA and 16 control subjects were studied. OSA subjects were treated with a titratable MAS for 6 months. Baseline plasma C-reactive protein, interleukin-1β, interleukin-10, interleukin-6, P-selectin, fibrinogen, D-dimer, plasminogen activator inhibitor-1 (PAI-1), thrombin-antithrombin complex, activated thrombin-activatable fibrinolysis inhibitor (TAFIa), 6-keto-PGF1α, glucose, and fibrin clot lysis time (CLT) were measured in all subjects. After 3 months of MAS therapy, measurements were repeated for the 22 patients, and after 6 months all measurements were repeated for all study subjects. RESULTS MAS treatment reduced significantly AHI at 3 months (24 vs 13.1/h) and further improved it at 6 months (13.1 vs 7.05/h). Compared with controls, OSA subjects had a significant higher baseline mean levels of fibrinogen, TAFIa, 6-keto-PGF1α, and glucose. MAS treatment significantly improved levels of IL-1β, D-dimer, TAFIa, and CLT. Despite residual apneas, MAS treatment group presented similar measured homeostatic and inflammatory levels to controls except for glucose. CONCLUSION Treatment with MAS in mild-to-moderate OSA subjects improves the inflammatory profile and homeostatic markers. CITATION Niżankowska-Jędrzejczyk A; Almeida FR; Lowe AA; Kania A; Nastałek P; Mejza F; Foley JH; Niżankowska-Mogilnicka E; Undas A. Modulation of inflammatory and hemostatic markers in obstructive sleep apnea patients treated with mandibular advancement splints: a parallel, controlled trial.
Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine | 2007
Ewa Nizankowska-Mogilnicka; Filip Mejza; A. Sonia Buist; William M. Vollmer; Wojciech Skucha; Rafal Harat; Andrzej Pajak; Jerzy Gasowski; Jakub Frey; Paweł Nastałek; Magdalena Twardowska; Joanna Janicka; Andrzej Szczeklik
Advances in respiratory medicine | 2012
Filip Mejza; Paweł Nastałek; Wojciech Skucha; Rafal Harat; Ewa Nizankowska-Mogilnicka
Polish archives of internal medicine | 2018
Filip Mejza; Paweł Nastałek; Zbigniew Doniec; Wojciech Skucha
Advances in Dermatology and Allergology | 2018
Paweł Nastałek; Adam Kurek; Agnieszka Almgren-Rachtan; Agnieszka Mastalerz-Migas; Zbigniew Doniec
Lekarz POZ | 2017
Zbigniew Doniec; Paweł Nastałek; Adam Kurek; Agnieszka Almgren-Rachtan
Advances in respiratory medicine | 2017
Wojciech Skucha; Filip Mejza; Paweł Nastałek; Zbigniew Doniec
american thoracic society international conference | 2010
Aleksander Kania; Agata Nizankowska-Jedrzejczyk; Paweł Nastałek; Filip Mejza; Adam Ćmiel; Teresa Iwaniec; Anna Gielicz; Marek Sanak; Andrzej Szczeklik; Ewa Nizankowska-Mogilnicka
american thoracic society international conference | 2010
Bernd Lamprecht; Michael Studnicka; Mary Ann McBurnie; Mike Allison; William M. Vollmer; Paweł Nastałek; Rune Nielsen; Wan C. Tan; Louisa Gnatiuc; A. S. Buist